Clinical Trial Update: Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating low dose interleukin-2 in patients with ischemic heart disease, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemic Heart Disease

Drugs mentioned

• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Cambridge University Hospitals NHS Foundation Trust | Conditions: Ischemic Heart Disease | Phase 1, Phase 2 | Status: COMPLETED